Passaro A - Search Results

1

Afatinib in first-line setting for NSCLC harbouring common EGFR mutations: new light after the preliminary results of LUX-Lung 7?

Passaro A, Pochesci A, Spitaleri G, Catania C, Noberasco C, Del Signore E, de Marinis F. Passaro A, et al. J Thorac Dis. 2016 Mar;8(3):E217-20. doi: 10.21037/jtd.2016.02.21. J Thorac Dis. 2016. PMID: 27076973 Free PMC article.

2

Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?

Passaro A, Cortesi E, de Marinis F. Passaro A, et al. Expert Rev Anticancer Ther. 2011 Oct;11(10):1587-97. doi: 10.1586/era.11.120. Expert Rev Anticancer Ther. 2011. PMID: 21999132 Review.

3

Erlotinib and gefitinib for elderly patients with advanced non-small-cell lung cancer.

Passaro A, Alesini D, Pochesci A, Cortesi E. Passaro A, et al. Anticancer Agents Med Chem. 2014 Jun;14(5):646-50. doi: 10.2174/187152061405140501101624. Anticancer Agents Med Chem. 2014. PMID: 23140355 Review.

4

Afatinib as first-line treatment for patients with advanced non-small-cell lung cancer harboring EGFR mutations: focus on LUX-Lung 3 and LUX-Lung 6 phase III trials.

Passaro A, Gori B, de Marinis F. Passaro A, et al. J Thorac Dis. 2013 Aug;5(4):383-4. doi: 10.3978/j.issn.2072-1439.2013.07.32. J Thorac Dis. 2013. PMID: 23991291 Free PMC article. No abstract available.

5

Vitamin supplementation in patients receiving pemetrexed for advanced non-small cell lung cancer.

de Marinis F, Passaro A, Clarke S. de Marinis F, et al. Among authors: passaro a. Lung Cancer. 2013 Dec;82(3):511. doi: 10.1016/j.lungcan.2013.09.003. Epub 2013 Sep 12. Lung Cancer. 2013. PMID: 24080011 No abstract available.

6

Afatinib-related nonhematologic adverse events: is common evaluation enough for now?

de Marinis F, Passaro A. de Marinis F, et al. Among authors: passaro a. J Clin Oncol. 2014 Mar 10;32(8):864-5. doi: 10.1200/JCO.2013.52.4538. Epub 2014 Feb 3. J Clin Oncol. 2014. PMID: 24493732 No abstract available.

7

Afatinib in NSCLC harbouring EGFR mutations.

de Marinis F, Catania C, Passaro A. de Marinis F, et al. Among authors: passaro a. Lancet Oncol. 2014 Apr;15(4):e148-9. doi: 10.1016/S1470-2045(13)70402-9. Lancet Oncol. 2014. PMID: 24694632 No abstract available.

8

Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies.

D'Antonio C, Passaro A, Gori B, Del Signore E, Migliorino MR, Ricciardi S, Fulvi A, de Marinis F. D'Antonio C, et al. Among authors: passaro a. Ther Adv Med Oncol. 2014 May;6(3):101-14. doi: 10.1177/1758834014521110. Ther Adv Med Oncol. 2014. PMID: 24790650 Free PMC article. Review.

9

management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysis.

Passaro A, Di Maio M, Del Signore E, Gori B, de Marinis F. Passaro A, et al. Clin Lung Cancer. 2014 Jul;15(4):307-12. doi: 10.1016/j.cllc.2014.04.006. Epub 2014 May 12. Clin Lung Cancer. 2014. PMID: 24954231

10

Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial.

de Marinis F, Vergnenegre A, Passaro A, Dubos-Arvis C, Carcereny E, Drozdowskyj A, Zeaiter A, Perez-Moreno P, Rosell R. de Marinis F, et al. Among authors: passaro a. Future Oncol. 2015;11(3):421-9. doi: 10.2217/fon.14.269. Future Oncol. 2015. PMID: 25675123 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

353 results

Search Page

Filters